Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Isil Altintas"'
Autor:
Jordan Blum, Alexander Muik, Isil Altintas, Friederike Gieseke, Aras Toker, Esther Breij, Tahamtan Ahmadi, Ugur Sahin, Kristel Kemper, Oezlem Tuereci, Kristina Nuermberger, Sina Fellermeier-Kopf, Andrea Imle, Anna-Lena Krause, Lidia Daszkiewicz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/5b2dfbe7a11a49c1a72650313cf5a53d
Autor:
Alexander Muik, Isil Altintas, Friederike Gieseke, Kristina B Schoedel, Saskia M Burm, Aras Toker, Theodora W. Salcedo, Dennis Verzijl, David Eisel, Christian Grunwitz, Lena M Kranz, Mathias Vormehr, David P.E. Satijn, Mustafa Diken, Sebastian Kreiter, Kate Sasser, Tahamtan Ahmadi, Özlem Türeci, Esther C.W. Breij, Maria Jure-Kunkel, Ugur Sahin
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis have changed the treatment paradigm for advanced solid tumors; however, many patients experience treatment resistance. In preclinical models 4-1BB co-stimulation synergizes with ICI by
Externí odkaz:
https://doaj.org/article/c2df5e33bb4545efb02c509f371c1d5a
Autor:
Maria Jure-Kunkel, Homer C Adams III, Kate Sasser, Mark Fereshteh, Alexander Muik, Isil Altintas, Friederike Gieseke, Aras Toker, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Dennis Verzijl, Kristina B Schoedel, Jordan M Blum, Bianca Sänger, Saskia M Burm, Eliana Stanganello, Vanessa M Spires, Fulvia Vascotto, Juliane Quinkhardt, Mustafa Diken, David P E Satijn, Sebastian Kreiter, Esther C W Breij
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/026b8577fc804412a127d45c0c573c04
Autor:
Maria Jure-Kunkel, Rachelle Kosoff, Mark Fereshteh, Alexander Muik, Isil Altintas, Friederike Gieseke, Kristina Schödel, Theodora Salcedo, Saskia Burm, Aras Toker, Lena Kranz, Mathias Vormehr, David Eisel, Özlem Türeci, Esther Breij, Tahamtan Ahmadi, Ugur Sahin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/eea14f7713674c8fb51f93a571e8bfb1
Autor:
Ignacio Melero, Maria Jure-Kunkel, Uğur Şahin, Tahamtan Ahmadi, Ulf Forssmann, Özlem Türeci, Kate Sasser, Eleni Lagkadinou, Gaurav Bajaj, Esther C.W. Breij, Sebastian Kreiter, David Satijn, Mustafa Diken, Mark Fereshteh, Edward N. van den Brink, Aras Toker, Theo S. Plantinga, Juliane Quinkhardt, Angelica Sette, Fulvia Vascotto, Dennis Verzijl, Eliana Stanganello, Saskia M. Burm, Theodora W. Salcedo, Bianca Sänger, Jordan M. Blum, Kristina B. Schoedel, Maria E. Rodriguez-Ruiz, Guzman Alonso, Patricia M. LoRusso, Emiliano Calvo, Corinne Maurice-Dror, Eytan Ben-Ami, Ravit Geva, Friederike Gieseke, Isil Altintas, Elena Garralda, Alexander Muik
Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77571654a67b8230111048825587e8ec
https://doi.org/10.1158/2159-8290.c.6549569
https://doi.org/10.1158/2159-8290.c.6549569
Autor:
Ignacio Melero, Maria Jure-Kunkel, Uğur Şahin, Tahamtan Ahmadi, Ulf Forssmann, Özlem Türeci, Kate Sasser, Eleni Lagkadinou, Gaurav Bajaj, Esther C.W. Breij, Sebastian Kreiter, David Satijn, Mustafa Diken, Mark Fereshteh, Edward N. van den Brink, Aras Toker, Theo S. Plantinga, Juliane Quinkhardt, Angelica Sette, Fulvia Vascotto, Dennis Verzijl, Eliana Stanganello, Saskia M. Burm, Theodora W. Salcedo, Bianca Sänger, Jordan M. Blum, Kristina B. Schoedel, Maria E. Rodriguez-Ruiz, Guzman Alonso, Patricia M. LoRusso, Emiliano Calvo, Corinne Maurice-Dror, Eytan Ben-Ami, Ravit Geva, Friederike Gieseke, Isil Altintas, Elena Garralda, Alexander Muik
Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e568b16421048c1e79b8dfceca7e687
https://doi.org/10.1158/2159-8290.22541198.v1
https://doi.org/10.1158/2159-8290.22541198.v1
Autor:
Alexander Muik, Homer C Adams, Friederike Gieseke, Isil Altintas, Kristina B Schoedel, Jordan M Blum, Bianca Sänger, Saskia M Burm, Eliana Stanganello, Dennis Verzijl, Vanessa M Spires, Fulvia Vascotto, Aras Toker, Juliane Quinkhardt, Mark Fereshteh, Mustafa Diken, David P E Satijn, Sebastian Kreiter, Tahamtan Ahmadi, Esther C W Breij, Özlem Türeci, Kate Sasser, Ugur Sahin, Maria Jure-Kunkel
Publikováno v:
Journal for immunotherapy of cancer. 10(6)
BackgroundDespite the preclinical promise of CD40 and 4-1BB as immuno-oncology targets, clinical efforts evaluating CD40 and 4-1BB agonists as monotherapy have found limited success. DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel investigational Fc-
Autor:
Alexander Muik, Elena Garralda, Isil Altintas, Friederike Gieseke, Ravit Geva, Eytan Ben-Ami, Corinne Maurice-Dror, Emiliano Calvo, Patricia M. LoRusso, Guzman Alonso, Maria E. Rodriguez-Ruiz, Kristina B. Schoedel, Jordan M. Blum, Bianca Sänger, Theodora W. Salcedo, Saskia M. Burm, Eliana Stanganello, Dennis Verzijl, Fulvia Vascotto, Angelica Sette, Juliane Quinkhardt, Theo S. Plantinga, Aras Toker, Edward N. van den Brink, Mark Fereshteh, Mustafa Diken, David Satijn, Sebastian Kreiter, Esther C.W. Breij, Gaurav Bajaj, Eleni Lagkadinou, Kate Sasser, Özlem Türeci, Ulf Forssmann, Tahamtan Ahmadi, Uğur Şahin, Maria Jure-Kunkel, Ignacio Melero
Publikováno v:
Scientia
Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting
Autor:
Kristina Schödel, Lena M. Kranz, Mark Fereshteh, Alexander Muik, Theodora Salcedo, Maria Jure-Kunkel, Mathias Vormehr, Friederike Gieseke, Aras Toker, Tahamtan Ahmadi, Rachelle Kosoff, Ugur Sahin, Esther C.W. Breij, David Eisel, Saskia M. Burm, Özlem Türeci, Isil Altintas
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Checkpoint inhibitors targeting the PD-1/PD-L1 axis (CPI) have changed the treatment paradigm and prognosis for patients with advanced solid tumors; however, many patients experience limited benefit due to treatment resistance. 4-1BB co-st
Autor:
Anthony A. Armstrong, Tom C. Nesspor, Joyce I. Meesters, Matthew Bunce, Isil Altintas, Sandra Verploegen, Janine Schuurman, Aran F. Labrijn, Sandeep Somani, Mark L. Chiu, Paul W. H. I. Parren
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-14 (2017)
Labrijn, A F, Meesters, J I, Bunce, M, Armstrong, A A, Somani, S, Nesspor, T C, Chiu, M L, Altintaş, I, Verploegen, S, Schuurman, J & Parren, P W H I 2017, ' Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models ', Scientific Reports, vol. 7, 2476 . https://doi.org/10.1038/s41598-017-02823-9
Scientific Reports
Labrijn, A F, Meesters, J I, Bunce, M, Armstrong, A A, Somani, S, Nesspor, T C, Chiu, M L, Altintaş, I, Verploegen, S, Schuurman, J & Parren, P W H I 2017, ' Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models ', Scientific Reports, vol. 7, 2476 . https://doi.org/10.1038/s41598-017-02823-9
Scientific Reports
Therapeutic concepts exploiting tumor-specific antibodies are often established in pre-clinical xenograft models using immuno-deficient mice. More complex therapeutic paradigms, however, warrant the use of immuno-competent mice, that more accurately